How is Nintedanib reimbursed by medical insurance?

Nintedanib (Nintedanib) is the only drug approved to be taken twice daily to treat adults with a lung disease called idiopathic pulmonary fibrosis (IPF) and to treat persistent pulmonary fibrosis. It is also used to slow down the decline of lung function in adults with systemic sclerosis-related interstitial lung disease (SSc-ILD). The original drug of nintedanib is sold in China as nintedanib ethanesulfonate soft capsules The name is on the market and enters the scope of Class B medical insurance, which is limited to patients with idiopathic pulmonary fibrosis (IPF) or systemic sclerosis-related interstitial lung disease (SSc-ILD) Reimbursement, SpecificationsThe price of each box of 150mg*30 tablets may be more than 4,000 yuan. The reimbursement ratio is different in different regions. The price after reimbursement may be different. Please consult the local medical insurance bureau or hospital for details.